Home
SXTP
SXTP News

Latest 60 Degrees Pharmaceuticals Inc. (SXTP) News on April 26, 2025

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

GlobeNewswire

4 days ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

Insider Monkey

16 days ago

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

GlobeNewswire

16 days ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

60 Degrees and Yale to progress tafenoquin for babesiosis

Pharmaceutical Technology

17 days ago

60 Degrees and Yale to progress tafenoquin for babesiosis

MT Newswires

18 days ago

Top Midday Gainers

MT Newswires

18 days ago

60 Degrees Pharmaceuticals Signs Patent License Deal to Develop Tafenoquine for Tick-Borne Disease Treatment

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

GlobeNewswire

18 days ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a month ago

60 Degrees Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

60 Degrees Pharmaceuticals Announces 2024 Annual Results

GlobeNewswire

a month ago

60 Degrees Pharmaceuticals Announces 2024 Annual Results

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

2 months ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 02/21/2025

MT Newswires

2 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires

2 months ago

60 Degrees Pharmaceuticals to Implement 1-for-5 Reverse Stock Split; Shares Down

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

GlobeNewswire

2 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 02/20/2025

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 02/19/2025

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 02/18/2025

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 02/14/2025

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 02/13/2025

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 02/12/2025

MT Newswires

2 months ago

60 Degrees Gets FDA Clearance to Import Antimalarial From Australia to Ensure Supply Continuity

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

GlobeNewswire

2 months ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 02/11/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 02/10/2025

Insiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55

Simply Wall St.

3 months ago

Insiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 02/07/2025

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

3 months ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 02/06/2025

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

3 months ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 02/05/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 02/04/2025

RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis

ACCESS Newswire

3 months ago

RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 02/03/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/31/2025

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

3 months ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/30/2025

60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

3 months ago

60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/29/2025

60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial

Clinical Trials Arena

3 months ago

60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial

MT Newswires

3 months ago

60 Degrees Pharmaceuticals Gets Investigational Review Board Approval for Babesiosis Phase 2 Study

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

GlobeNewswire

3 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/28/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/27/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/24/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/23/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/22/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/21/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/17/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/16/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/15/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/14/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/13/2025

60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study

TipRanks

4 months ago

60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 01/09/2025

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

GlobeNewswire

4 months ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 01/08/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 01/07/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 01/06/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 01/03/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/31/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/30/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/27/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/26/2024

60 Degrees, Tufts Medical Center announces patent license agreement

TipRanks

4 months ago

60 Degrees, Tufts Medical Center announces patent license agreement

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/24/2024

MT Newswires

4 months ago

60 Degrees Pharmaceuticals, Tufts Medical Center Sign Patent License Deal Over Potential Babesiosis Treatment

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

GlobeNewswire

4 months ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/23/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/20/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/19/2024

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital

GlobeNewswire

5 months ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

5 months ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

5 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates

Zacks

5 months ago

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

GlobeNewswire

5 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

GlobeNewswire

7 months ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

MT Newswires

8 months ago

60 Degrees Pharmaceuticals Closes $4 Million Private Placement

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

8 months ago

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

8 months ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire

8 months ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

8 months ago

60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates

Zacks

8 months ago

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

GlobeNewswire

8 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?

Insider Monkey

8 months ago

Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

GlobeNewswire

8 months ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

GlobeNewswire

9 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

GlobeNewswire

9 months ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals enters deals for babesiosis treatment trial

Clinical Trials Arena

9 months ago

60 Degrees Pharmaceuticals enters deals for babesiosis treatment trial

MT Newswires

9 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires

9 months ago

Sector Update: Health Care

MT Newswires

9 months ago

Top Midday Gainers

MT Newswires

9 months ago

60 Degrees Signs Testing Deals for Potential Babesiosis Drug -- Shares Rise Pre-Bell

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

GlobeNewswire

9 months ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

GlobeNewswire

10 months ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

GlobeNewswire

10 months ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

GlobeNewswire

10 months ago

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

Business Wire

a year ago

Net Asset Value(s)

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

Newsfile

a year ago

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

Dstny honored with 'Employee Wellbeing Award'

PR Newswire

a year ago

Dstny honored with 'Employee Wellbeing Award'

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

Business Wire

a year ago

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

Share on Social Networks: